Oncolytic Virotherapy: Turning Anti-Viral Immunity to Anti-Cancer

Time: 1:30 pm
day: Day One


  • Reviewing requirements for a good oncolytic virus including, potent tumor specific lytic activity to release sufficient amount of tumor antigens, strong regulation on tumor microenvironment to convert an anti-viral immunity to anti-tumor
  • Reviewing of the Virogin Biotech oncolytic virus pipeline which is more potent in causing tumor lysis while remaining highly tumor specific [Transcription and Translation Dual Regulation (TTDR)]
  • Showcasing combining oncolytic virotherapy with other therapeutic modalities, especially various checkpoint inhibitors and immune cell therapies